checkAd
    Startseite > Aktien > Tempest Therapeutics > Nachrichten
    Tempest Therapeutics Aktie
    3,0700
     
    EUR
    +1,59 %
    +0,0480 EUR
    Letzter Kurs 31.05.24 Tradegate
    3,0000
     
    EUR
    667 STK
    Geldkurs 31.05.24
    3,1380
     
    EUR
    637 STK
    Briefkurs 31.05.24
    ISIN: US87978U1088 · WKN: A3CSM8 · SYM: 3OS · USA

    Neueste Nachrichten

    Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
    31.05.24 · Business Wire (engl.) · Tempest Therapeutics
    Tempest to Participate in Upcoming Investor Conferences
    21.05.24 · globenewswire · Tempest Therapeutics
    Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
    09.05.24 · globenewswire · Tempest Therapeutics
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    26.04.24 · globenewswire · Tempest Therapeutics
    Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
    09.04.24 · globenewswire · Tempest Therapeutics
    Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
    04.04.24 · globenewswire · Tempest Therapeutics
    Tempest Reports Year End 2023 Financial Results and Provides Business Update
    19.03.24 · globenewswire · Tempest Therapeutics
    Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
    14.03.24 · Business Wire (engl.) · Tempest Therapeutics
    Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
    12.03.24 · globenewswire · Tempest Therapeutics
    Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
    05.03.24 · globenewswire · Tempest Therapeutics
    Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
    26.02.24 · globenewswire · Tempest Therapeutics
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    02.02.24 · globenewswire · Tempest Therapeutics